Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.42 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10758515 | 0.75 | AR (0.35) | KMT2A | |
| SCHEMBL16404341 | 0.74 | PARP1 (0.62) | PARP1TNKS2QTRT1TNKSALDH1A1 | |
| SCHEMBL4558816 | 0.72 | CDC7 (0.47) | PARP1TNKS2QTRT1TNKSKDM4E | |
| SCHEMBL28507693 | 0.72 | PARP1 (0.56) | PARP1TNKS2QTRT1TNKSALDH1A1 | |
| SCHEMBL28501122 | 0.72 | PARP1 (0.58) | PARP1TNKS2QTRT1TNKSKDM4E | |
| SCHEMBL12459009 | 0.71 | CDC7 (0.67) | — | |
| SCHEMBL29499006 | 0.71 | PARP1 (0.55) | PARP1TNKS2QTRT1TNKS | |
| SCHEMBL30496105 | 0.70 | PARP1 (0.54) | PARP1TNKS2QTRT1TNKSROCK2 | |
| SCHEMBL7713954 | 0.70 | PARP1 (0.54) | PARP1TNKS2QTRT1TNKSROCK2 | |
| SCHEMBL5051433 | 0.69 | ESR1 (0.51) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | PARP1 350/4885TNKS2 284/4885QTRT1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.